Kimon Bekelis1, Jeremy Smith2, Weiping Zhou2, Todd A MacKenzie2,3,4, David W Roberts1,5,6, Jonathan Skinner2,7, Nancy E Morden2,4,6. 1. Section of Neurosurgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. 2. The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, USA. 3. Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. 4. Department of Community and Family Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. 5. Department of Neurology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. 6. Geisel School of Medicine at Dartmouth, Hanover, NH, USA. 7. Department of Economics, Dartmouth College, Hanover, NH, USA.
Abstract
BACKGROUND: Statins have been shown to decrease aneurysm progression and rupture in two experimental settings: animals with cerebral aneurysm and humans with abdominal aortic aneurysms. AIMS: To investigate statin use and outcomes in humans with unruptured cerebral aneurysms through Medicare administrative data. METHODS: We used a 40% random sample Medicare denominator file and corresponding inpatient, outpatient (2003-2011), and prescription (2006-2011) claims to conduct a retrospective cohort study of patients diagnosed with unruptured cerebral aneurysms, between 2003 and 2011. We used propensity score-adjusted models to investigate the association between statin use and risk of subarachnoid hemorrhage. Secondary analyses repeated the main models stratified on tobacco use status and separately assessed other composite outcomes. RESULTS: We identified 28 931 patients with unruptured cerebral aneurysms (average age 72·0 years, 72·6% female); mean follow-up was 30·0 months; 41·3% used statins. Overall, 593 patients developed subarachnoid hemorrhage, and 703 underwent treatment before subarachnoid hemorrhage. Current or recent statin use was not associated with a difference in subarachnoid hemorrhage risk (odds ratio, 1·03; 95% conflict of interest 0·86-1·23); models stratified on tobacco use status were nearly identical. No association was observed between statin use and the composite outcome of subarachnoid hemorrhage or aneurysm treatment (odds ratio, 0·94; 95% conflict of interest, 0·84-1·06). The risk of subarachnoid hemorrhage or out-of-hospital death was lower among statin users (odds ratio, 0·69; 95% conflict of interest, 0·64-0·74). CONCLUSIONS: Statin use by patients with unruptured cerebral aneurysms was not associated with subarachnoid hemorrhage risk. Given the prior animal experimental studies demonstrating a protective effect, further prospective studies are needed to investigate the potential relationship.
BACKGROUND: Statins have been shown to decrease aneurysm progression and rupture in two experimental settings: animals with cerebral aneurysm and humans with abdominal aortic aneurysms. AIMS: To investigate statin use and outcomes in humans with unruptured cerebral aneurysms through Medicare administrative data. METHODS: We used a 40% random sample Medicare denominator file and corresponding inpatient, outpatient (2003-2011), and prescription (2006-2011) claims to conduct a retrospective cohort study of patients diagnosed with unruptured cerebral aneurysms, between 2003 and 2011. We used propensity score-adjusted models to investigate the association between statin use and risk of subarachnoid hemorrhage. Secondary analyses repeated the main models stratified on tobacco use status and separately assessed other composite outcomes. RESULTS: We identified 28 931 patients with unruptured cerebral aneurysms (average age 72·0 years, 72·6% female); mean follow-up was 30·0 months; 41·3% used statins. Overall, 593 patients developed subarachnoid hemorrhage, and 703 underwent treatment before subarachnoid hemorrhage. Current or recent statin use was not associated with a difference in subarachnoid hemorrhage risk (odds ratio, 1·03; 95% conflict of interest 0·86-1·23); models stratified on tobacco use status were nearly identical. No association was observed between statin use and the composite outcome of subarachnoid hemorrhage or aneurysm treatment (odds ratio, 0·94; 95% conflict of interest, 0·84-1·06). The risk of subarachnoid hemorrhage or out-of-hospital death was lower among statin users (odds ratio, 0·69; 95% conflict of interest, 0·64-0·74). CONCLUSIONS: Statin use by patients with unruptured cerebral aneurysms was not associated with subarachnoid hemorrhage risk. Given the prior animal experimental studies demonstrating a protective effect, further prospective studies are needed to investigate the potential relationship.
Authors: Craig D Ferguson; Paula Clancy; Bernard Bourke; Philip J Walker; Anthony Dear; Tim Buckenham; Paul Norman; Jonathan Golledge Journal: Am Heart J Date: 2010-02 Impact factor: 4.749
Authors: Felix J V Schlösser; Marco J D Tangelder; Hence J M Verhagen; Geert J M G van der Heijden; Bart E Muhs; Yolanda van der Graaf; Frans L Moll Journal: J Vasc Surg Date: 2008-04-28 Impact factor: 4.268
Authors: O Schouten; J H H van Laanen; E Boersma; R Vidakovic; H H H Feringa; M Dunkelgrün; J J Bax; J Koning; H van Urk; D Poldermans Journal: Eur J Vasc Endovasc Surg Date: 2006-03-06 Impact factor: 7.069
Authors: Roelof Risselada; Huub Straatman; Fop van Kooten; Diederik W J Dippel; Aad van der Lugt; Wiro J Niessen; Azadeh Firouzian; Ron M C Herings; Miriam C J M Sturkenboom Journal: Stroke Date: 2009-06-11 Impact factor: 7.914
Authors: Anil Can; Victor M Castro; Dmitriy Dligach; Sean Finan; Sheng Yu; Vivian Gainer; Nancy A Shadick; Guergana Savova; Shawn Murphy; Tianxi Cai; Scott T Weiss; Rose Du Journal: Stroke Date: 2018-04-05 Impact factor: 7.914